It’s doubtful that anyone’s ever made a serious claim to the legal profession’s simplicity. It’s right up there with medicine and economics as one of the more complex aspects of our society. And that’s exactly why I found a recent case involving Laidlaw & Company so interesting. The investment bank is up against Relmada Therapeutics, a clinical-stage medical company. And so far it seems to be going in their favor. The most recent incident in the trail was a temporary restraining order and associated injunction against Laidlaw. It’d been decided that they were spreading deliberately misleading information about the case. But at the same time, one person’s idea of misleading information can simply be the other side of a complex story.
I was quite curious to see exactly where Laidlaw was coming from. And I figured that there was nowhere better to get their side of things than their own website. And that intuition proved to be a wise choice. Right from the start it helped to clarify some things about Laidlaw. For one thing, the fact that they were involved with Relmada wasn’t a fluke. The company has a long history of helping to finance various projects involved with medical research. Anyone familiar with the medical industry knows how important it is to find people willing to help expedite the research process.
This aspect of Laidlaw’s overall business plan was further illuminated when I looked for information about the company’s principals. Not only did the company have a long history of helping out with medical research, Matthew Eitner and James Ahern did as well. They have a lengthy history posted right on the site. Their personal interest in helping fund medical research and associated projects really helped to inform my opinion about the company as a whole. The reasons why Laidlaw has such an intense interest in Relmada is more clear within that context. It makes sense that a company which is heavily involved with medical concerns would want a hands on approach.